Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q3 2019 · 10-Q
Revenue$60.15K$60.15K— vs Q3 2018 Net Income-$2.03M-$2.03MN/M vs Q3 2018 EPS Diluted-$0.05-$0.05N/M vs Q3 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
-$2,020,663
N/M
Operating Cash Flowderived-$1,543,346N/M Free Cash Flowderived-$1,744,167N/M Margins · derivedGross margin-66.9%
Operating margin-3359.2%
Net margin-3367.7%
ended Sep 30, 2019 · filed Nov 14, 2019 · 45 d after period end